Why access degradation products?
The safety of a drug is impacted by it’s susceptibility to form degradation products. To meet regulatory guidelines, significant API degradation products and drug substance impurities must be identified. This involves isolation and definitive structure elucidation of the degradate, typically by NMR spectroscopy. In addition, pure material is needed for determining the relative response factor (RRF) of the degradate compared to the API, so that the weight % formation of degradation products can be accurately calculated. Pure degradates may also be required for use as analytical standards, or for safety assessments.
Oxidative degradation pathways commonly result in the most complex reaction profiles, highlighted by Nanda and colleagues who state that, “…faster and practical ways of enriching an API with relevant oxidative degradates and their isolation in pure form is highly desirable.” Thus, availability of an oxidation toolkit incorporating broad chemistry, is beneficial for rapidly generating oxidised products.
Ref: Nanda et al., 2019. Enrichment of Relevant Oxidative Degradation Products in Pharmaceuticals With Targeted Chemoselective Oxidation. Journal of Pharmaceutical Sciences, 108, 4, 1466-1475.
Manufacturing and Degradation Impurities - Services at Hypha
Identification of Fluoxetine Storage Impurities
Hypha purified and identified two sucralose conjugates of fluoxetine, formed during a study where the drug had been stored at 50oC for 2 months. Simulation of the reaction at 50oC for 7 days permitted purification and identification of two sucralose conjugates. Subtle differences in the NMR spectra revealed the presence of stereoisomers resulting from the reaction of sucralose with racemic fluoxetine.
Chemical Oxidation of Risperidone
Tomar et al. report that the two major degradants formed from risperidone are an N-oxide and 9-hydroxy risperidone (also known as paliperidone, the primary active metabolite of rispiridone sold at Invega).
Risperidone was screened against a diverse set of oxidation conditions and the products analysed by LC-MS. Reactions in which oxidation products were observed were scaled up, resulting in the isolation of 10 different oxidation products. Structures were elucidated through use of cryoprobe NMR.
Both the N-oxide and 9-hydroxy risperidone major degradation products were produced (shaded) along with 8 other oxidised derivatives.
Ref: Tomar et al., 2004. Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms. Journal of Pharmaceutical and Biomedical Analysis, 36, (1), 231-235
Introducing oxygen into a drug candidate late in the optimisation process has several applications including exploration of SAR (structure-activity relationships) and the ability to access derivatives that may possess superior properties such as improved metabolic stability and LLE (ligand-lipophilicity efficiency). Biocatalysis can provide access to chemical space in a complementary manner to chemical synthesis and provide a “one-experiment” solution to accessing multiple derivatives in parallel. This poster illustrates the application of a new biocatalysis kit, PolyCYPs®, to enable parallel synthesis of hydroxylated derivatives of drugs.
If clearance mechanisms of the test drug results in sufficient quantities of the major metabolites in biological material such as faeces or urine, purification and subsequent identification of metabolites from such matrices is possible. One such project undertaken at Hypha resulted in tens of milligrams of the R- and S-O-glucuronides of carisbamate, a neuromodulator developed by SK Life Science, which were purified to >95% purity from 150 ml of urine using a three-step purification method.
Find out about our other services
We worked with Hypha discovery to synthesize metabolites via a chemical approach in enough quantities for pharmacology studies for one of our products. Hypha has well understood our request and provided a very good quality of service in time, in quantity and quality with the needed level of regular communication. We will work certainly with them in the future and will recommend them.
Dr. Laure Navarre, Director Process Chemistry
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.